BioCardia Inc美国招股说明书（2025年4月4日版）

Our common stock is listed on the Nasdaq Capital Market under the symbol "BCDA." The last reported sale price was $2.27 per share on April 2, 2025. This prospectus supplement updates the maximum aggregate offering amount of shares eligible for sale to $1,813,844, in addition to the approximately $2.7 million of gross proceeds received prior to this date. The aggregate market value of outstanding common stock held by non-affiliates is approximately $11.7 million, based on 4,682,184 shares, with 546,954 shares held by non-affiliates at a per share price of $2.84 (based on the closing sale price on February 14, 2025). Under this prospectus supplement and the Prospectus, we are currently eligible to offer and sell up to an aggregate of approximately $1,813,844 of our securities. The aggregate offering amount of securities sold will not exceed one-third of the aggregate market value of our common stock held by non-affiliates in any 12 calendar month period, as long as the aggregate market value of our common stock held by non-affiliates is less than $75.0 million. During the 12 calendar month period ending on and including the date hereof, we have sold approximately $2.1 million of our shares of common stock pursuant to General Instruction I.B.6 of Form S-3. Investing in our common stock involves significant risk, and investors should review the risk factors described in the Initial Prospectus Supplement and the accompanying base prospectus. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved these securities or determined if this prospectus supplement is truthful or complete.